High compliance with Optune linked to greatest survival benefit for glioblastoma
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
There is a dose response curve. (Which also should convince the naysayers that the device is effective) The better the compliance, the better the patients do. They have been saying 75% is the target compliance rate but the new data shows that 90% should be the target. Those patients who had a compliance rate of 90% or more, had a survival rate of 29.3% at 5 years, compared to the control group (temodar) which had a 4.5% survival rate, an almost 650% increase in survival rate.
With a compliance of 70-80%, the 5 year survival rate drops to 19.9%. Still much better than the control group... so don't stress too much if you can't hit the 90%, but try.
Posted on: 11/21/2017
Click HERE to return to brain tumor news headlines